Karyopharm Therapeutics
KPTI
KPTI
136 hedge funds and large institutions have $1.31B invested in Karyopharm Therapeutics in 2020 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
136
Holders Change
-10
Holders Change %
-6.85%
% of All Funds
3%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.2%
New
28
Increased
56
Reduced
37
Closed
35
Calls
$22.2M
Puts
$21.7M
Net Calls
+$485K
Net Calls Change
-$353K
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$62.5M |
| 2 |
Alkeon Capital Management
New York
|
+$39.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$21.1M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.2M |
| 2 |
O
OrbiMed
New York
|
-$11.9M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$11.3M |
| 4 |
Two Sigma Investments
New York
|
-$6.06M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$5.67M |
